The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients

Hemodialysis International

Volumn 9, Issue 3, 2005, Pages 255-263

  Berns, Jeffrey S ^a   Fishbane, Steven ^b   Elzein, Hafez ^c   Lynn, Robert I ^d   Deoreo, Peter B ^e   Tharpe, David L ^f   Meisels, Ira S ^g  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c AMGEN INC   (United States)

^d Bronx Dialysis Center   (United States)

^e Centers for Dialysis Care   (United States)

^f Alabama Psychiatric Services   (United States)

^g ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Anemia; Health policy

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANEMIA; EPOETIN ALFA; FEMALE; HEALTH POLICY; HEMATOCRIT; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 23644462650     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1492-7535.2005.01139.x     Document Type: Article

References (21)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Friedman EA, Graber SE, Haley NR, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111(12):992-1000.
2. National Kidney Foundation. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997; 30(Suppl 3):S192-S240.
3. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001; 37(Suppl 1): S182-S238.
4. Kimmel PL, Greer JW, Milam RA, Thamer M. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol. 2000; 20(4):335-344.
5. US Renal Data System. USRDS 2001 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2001; 38(Suppl 3):S1-S248.
6. Cotter DJ, Thamer M, Kimmel PL, Sadler JH. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990 to 1996. Kidney Int. 1998; 54(6):2129-2139.
7. Griffiths RI, Powe NR, Greer J, de Lissovoy G, Anderson GF, Whelton PK, Watson AJ, Eggers PW. A review of the first year of Medicare coverage of erythropoietin. Health Care Financ Rev. 1994; 15(3):83-102.
8. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998; 32(6 Suppl 4): S133-S141.
9. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben J, Constantini E. United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis. 2002; 39(4):784-795.
10. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF Jr. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol. 2002; 13(5):1288-1295.
11. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF. Anemia management of adult hemodialysis patients in the US results: From the 1997 ESRD Core Indicators Project. Kidney Int. 2000; 57(2):578-589.
12. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003; 64(4):1514-1521.
13. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003; 41(1):111-124.
14. ERA/EDTA. European best practices guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999; 14(Suppl 5): 1-50.
15. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl 2):ii1-47.
16. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990; 263(6):825-830.
17. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000; 11(2):335-342.
18. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10(3):610-619.
19. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999; 10(6):1309-1316.
20. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12(11):2465-2473.
21. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol. 1995; 43(3):184-188.